Glenmark Launches Tiogiva Tiotropium Bromide Dry Powder Inhaler In Uk

Glenmark Pharmaceuticals Has Launched A Bioequivalent Version Of Tiotropium Bromide Dry Powder Inhaler (Dpi) Under The Brand Name &Ndash; Tiogiva, In The Uk For The Treatment Of Chronic Obstructive Pulmonary Disease (Copd).According To Data From Iqvia, Tiotropium Dpi Had A Market Size Of $ 450 Million In The Eu In The 12 Month Period Ended September 2020.Glenmark&Rsquo;S Subsidiary, Glenmark Pharmaceuticals Europe Had Entered Into A Strategic, Exclusive In-Licensing Arrangement For Marketing Generic Tiotropium Bromide Dpi In Western Europe And The Uk In August 2018. Glenmark Is Planning Subsequent Launches Of The Product Across Markets In Western Europe Under The Brand Name Tiogiva In Ireland, Sweden, Finland And Norway; Tavulus In Denmark, Spain, And Netherlands; And Tiotropium Glenmark In Germany.Tiotropium Bromide Dpi Is A Bioequivalent Version Of Boehringer Ingelheim&Rsquo;S Spiriva Handihaler And Is Used In The Treatment Of Copd.This Is The Second Inhalation Product In-Licensed By Glenmark For The European Market After Stalpex (Fluticasone/ Salmeterol) Dry Powder Inhaler.&Ldquo;We Are Glad To Introduce Tiogiva, One Of The First Bioequivalent Drugs To Be Launched In Europe For Treatment Of Copd. Respiratory Medicine Is A Key Area Of Focus For Glenmark And The Launch Of This Product Will Enable Us To Improve Access To Copd Treatment By Providing An Effective And High-Quality Treatment Option To Patients In The Uk And Western Europe,&Rdquo; Said Achin Gupta, Evp &Amp; Business Head Of Emea-L, Glenmark Pharmaceuticals.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!